Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Carmen Barile"'
Autor:
Henrik E. Poulsen, Søren A. Jensen, Felice Pasini, Roberto Padrini, Carmen Barile, Laura Bertolaso, Espen Jimenez-Solem, Morten Petersen, Kasper Broedbaek, Jon T. Andersen, Ulla B. Vogel, Ben Vainer, Milena Gusella, Shoaib Afzal
Purpose: The purpose of this study was to investigate whether specific combinations of polymorphisms in genes encoding proteins involved in 5-fluorouracil (5-FU) pharmacokinetics and pharmacodynamics are associated with increased risk of treatment-in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7693df2b679f51d8779a3236568984e9
https://doi.org/10.1158/1078-0432.c.6519110
https://doi.org/10.1158/1078-0432.c.6519110
Autor:
Henrik E. Poulsen, Søren A. Jensen, Felice Pasini, Roberto Padrini, Carmen Barile, Laura Bertolaso, Espen Jimenez-Solem, Morten Petersen, Kasper Broedbaek, Jon T. Andersen, Ulla B. Vogel, Ben Vainer, Milena Gusella, Shoaib Afzal
Supplementary Figure S1; Supplementary Tables S1-S4.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1882291b0c477ef38ab1f3a80b7e5259
https://doi.org/10.1158/1078-0432.22442372
https://doi.org/10.1158/1078-0432.22442372
Autor:
Emilia Durante, Vittorina Zagonel, Antonella Facchinetti, Michele Aieta, Alberto Diminutto, Carlo Gatti, Maurizio Nicodemo, Anna Paola Fraccon, Cristina Pegoraro, Claudia Mucciarini, Alessandra Bearz, Marco Maruzzo, Francesco Massari, Vincenza Conteduca, Rita Zamarchi, Umberto Basso, Ugo De Giorgi, Carmen Barile, Elisabetta Rossi, Matteo Santoni, Pasquale Fiduccia, Alessandra Perin, Teodoro Sava
Publikováno v:
Oncologist
Background Circulating tumor cells (CTCs) correlate with adverse prognosis in patients with breast, colorectal, lung, and prostate cancer. Little data are available for renal cell carcinoma (RCC). Materials and Methods We designed a multicenter prosp
Autor:
Marco, Maruzzo, Francesco, Pierantoni, Alberto, Bortolami, Dario, Palleschi, Andrea, Zivi, Maurizio, Nicodemo, Donata, Sartori, Rocco, De Vivo, Fable, Zustovich, Davide, Bimbatti, Davide, Pastorelli, Giuseppe Dione, Vultaggio, Mariella, Soraru', Melissa, Ballestrin, Caterina, Modonesi, Paola, Randisi, Carmen, Barile, Gino, Perri, Umberto, Basso, Vittorina, Zagonel
Publikováno v:
Targeted oncology. 17(4)
Second- or third-line treatment options for metastatic renal cell carcinoma (mRCC) have dramatically changed in the last few years. There are no criteria for the choice between nivolumab and cabozantinib, which both demonstrated overall survival (OS)
Autor:
Cristina Falci, Cristina Oliani, Yasmina Modena, Barbara Corso, Caterina Modonesi, Silvia Toso, Donatella Da Corte Z, Elisabetta Cretella, AnnaPaola Fraccon, Antonella Brunello, Romana Segati, Laura Bertolaso, Milena Gusella, Carmen Barile, Roberto Padrini, Felice Pasini, Giovanni De Rosa, Nadia Minicuci
Publikováno v:
Pharmacology Research & Perspectives
In previous studies, steady‐state Z‐endoxifen plasma concentrations (ENDOss) correlated with relapse‐free survival in women on tamoxifen (TAM) treatment for breast cancer. ENDOss also correlated significantly with CYP2D6 genotype (activity scor
Autor:
Yasmina Modena, E. Pezzolo, Carmen Barile, F Pasini, Giorgio Crepaldi, Milena Gusella, Daniela Menon, F. La Russa, Anna Paola Fraccon
Publikováno v:
The Pharmacogenomics Journal. 18:14-22
The role of genetic molecular markers in neoadjuvant treatment for locally advanced esophageal cancer has been reviewed, focusing strictly on concurrent chemoradiation protocols followed by surgery. Eleven studies evaluated the role of mRNA expressio
Autor:
Andrea Zivi, Carmen Barile, Umberto Basso, Davide Pastorelli, Vittorina Zagonel, Giulia Zanchetta, Donata Sartori, Davide Bimbatti, Caterina Modonesi, Paola Randisi, Gino Perri, Rocco De Vivo, Dario Palleschi, G. Vultaggio, Fable Zustovich, Alberto Bortolami, Marco Maruzzo, Melissa Ballestrin, Mariella Sorarù, Maurizio Nicodemo
Publikováno v:
Journal of Clinical Oncology. 39:290-290
290 Background: Second (2L) or third-line (3L) treatment options for mRCC have dramatically changed in the last years. The standard of care as per Italian Regulatory Agencies approvals is N or C. To date, there are no criteria for the choice between
Autor:
Felice Pasini, Daniela Menon, Carmen Barile, Donatella Caruso, Laura Bertolaso, Giuseppe Corona, Yasmina Modena, Giorgio Crepaldi, A. Bononi, Anna Paola Fraccon, Milena Gusella, Giorgia Anna Telatin, Roberto Spezzano, Roberto Padrini
Publikováno v:
Cancer chemotherapy and pharmacology. 83(3)
This study investigated correlations of the clinical outcomes of oral metronomic vinorelbine (VNR) with VNR pharmacokinetics and MDR1 polymorphisms. Eighty-two patients with metastatic non-small cell lung cancer (NSCLC) unfit for standard chemotherap
Autor:
Milena Gusella, A. Bononi, Carmen Barile, Felice Pasini, Yasmina Modena, Donatella Caruso, Francesca La Russa, Roberto Padrini, Laura Bertolaso, Giuseppe Corona, Anna Paola Fraccon, Daniela Menon, Giorgio Crepaldi, Roberto Spezzano
Publikováno v:
Investigational new drugs. 36(5)
Background Oral metronomic therapy (OMV) is particularly suitable for palliative care, and schedules adapted for unfit patients are advisable. This study investigated the effects of oral vinorelbine given every other day without interruption and its
Autor:
Vilmos Adleff, István Láng, Milena Gusella, Jon Trærup Andersen, Morten Petersen, Kasper Brødbæk, Barna Budai, Erika Hitre, Shoaib Afzal, Laura Bertolaso, Enikő Orosz, Ulla Vogel, Carmen Barile, Judit Kralovánszky, Henrik E. Poulsen, Ben Vainer, Roberto Padrini, Felice Pasini, Søren Astrup Jensen, Espen Jimenez-Solem
Publikováno v:
Pharmacogenomics. 12:1257-1267
Aim: The purpose of this study was to investigate whether specific combinations of polymorphisms in 5-fluorouracil (5-FU) metabolism-related genes were associated with outcome in 5-FU-based adjuvant treatment of colorectal cancer. Methods: We analyze